Inovio Pharmaceuticals
183 hedge funds and large institutions have $197M invested in Inovio Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 25 closing their positions.
19% more call options, than puts
Call options by funds: $2.24M | Put options by funds: $1.89M
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
1% more funds holding
Funds holding: 182 → 183 (+1)
0.38% more ownership
Funds ownership: 3.88% → 4.25% (+0.38%)
2% less capital invested
Capital invested by funds: $201M → $197M (-$3.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$10.3M |
| 2 |
Millennium Management
New York
|
+$4.19M |
| 3 |
BlackRock
New York
|
+$3.29M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.14M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$2.79M |
| 2 |
Two Sigma Advisers
New York
|
-$1.79M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$1.77M |
| 4 |
Citigroup
New York
|
-$1.58M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.56M |
INO Hedge Fund Activity: Q4 2022 in Review
183 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2022, worth a combined $197M — down 1.8% from $201M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new INO positions and 25 closed out — a net gain of 4 holders — while 57 added to existing stakes and 49 trimmed.
The largest buyer was State Street, adding an estimated $10.3M. The largest seller was Two Sigma Investments, cutting an estimated $2.79M.
- 183 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2022, up from 182 in Q3 2022.
- Funds reported $197M of Inovio Pharmaceuticals stock for Q4 2022, down 1.8% quarter-over-quarter.
- 29 funds opened new Inovio Pharmaceuticals positions in Q4 2022 and 25 closed out, a net change of +4 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2022 was State Street, an estimated $10.3M added.
- The largest Inovio Pharmaceuticals seller in Q4 2022 was Two Sigma Investments, an estimated $2.79M sold.
Based on aggregated 13F filings for Q4 2022.